Russian Parliament to restrict imports of unregistered drugs

30 October 2014

The Russian National Parliament (State Duma) plans to impose a ban on the imports of unregistered drugs to Russia with the purpose of sales and making a profit in the country, according to the press-service of the Duma.

It is planned that such an amendment will be included in the existing federal bill “On responsibility for sales of unlicensed drugs or medical products and their production in Russia.”

At the same time, according to Irina Yarovaya, a member of the State Duma and one of the initiators of the new amendments, imposition of the ban will not result in the disappearance of such drugs from the Russian market. She added that people suffering from certain diseases that require the purchase such drugs will be able to receive or buy them through the Ministry of Health and several charitable foundations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical